The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
* This Week in the Journal
 February 4, 2010
 Audio Icon Audio Summary
*
Correspondence
* Intensity of Continuous Renal-Replacement Therapy
* Functional Status of Elderly Adults Receiving Dialysis
* Accuracy of Financial Disclosures Reported by Physicians
* Ankle–Brachial Index and Peripheral Arterial Disease
* Transfusion of RhD-Positive Blood in "Asia Type" DEL Recipients
* A Wii Fracture
*
Continuing Medical Examination
* A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
* Jet Lag
* Under Pressure
Original Articles
Placebo-Controlled Study of Oral Fingolimod in Relapsing Multiple Sclerosis

In this 24-month, randomized trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod reduced the rates of relapse and disability progression, as compared with placebo. Adverse events reported in patients treated with fingolimod included bradycardia, atrioventricular conduction block, macular edema, elevations in liver-enzyme levels, and mild hypertension.

Related Editorial


Original Articles
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

In this 12-month trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod was more effective than intramuscular interferon beta-1a in reducing relapse rates. Adverse events associated with fingolimod included herpesvirus infections (two fatal infections), atrioventricular block, macular edema, skin cancer, and liver-enzyme elevation.

Related Editorial


Original Articles
Cladribine or Placebo for Relapsing Multiple Sclerosis

In this 96-week, placebo-controlled trial, oral cladribine reduced relapse rates and lowered the risk of sustained disability in patients with relapsing–remitting multiple sclerosis. Patients who were treated with cladribine had large reductions in lymphocyte counts and more infections, including herpes zoster and one death from reactivation of tuberculosis.

Related Editorial


Original Articles
Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2

Suppressive therapy for herpes simplex virus 2 (HSV-2) has also been shown to reduce the levels of human immunodeficiency virus type 1 (HIV-1). However, in this placebo-controlled trial involving 3408 African couples who were discordant in serologic status for these two viruses, daily treatment with acyclovir did not reduce the frequency of HIV-1 transmission, despite a reduction in HIV-1 RNA levels and a 73% reduction in the occurrence of HSV-2–positive genital ulcers.


Clinical Practice
Jet Lag

A 55-year-old physician is planning a trip from Los Angeles to London to attend a scientific conference. His previous trip to Europe was complicated by sleepiness during meetings and difficulty falling asleep and remaining asleep at night. He wants to know what he can do to avoid jet lag. What would you advise?


Clinical Problem-Solving
Under Pressure

A 25-year-old woman presented to her local hospital with dyspnea. She described a 2-year history of progressive shortness of breath on exertion. Within the previous 3 days, her condition had deteriorated to the point that she was unable to leave her bedroom without having dyspnea.


Sounding Board
Comparative Effectiveness and Health Care Spending — Implications for Reform

In this Sounding Board article, the authors argue that health care costs can be reduced without a negative effect on quality by reducing spending on interventions that are not cost-effective.


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.